The clinical and experimental studies on the causes and the development of treatments of the neonatal thrombosis and DIC

对新生儿血栓形成和弥散性血管内凝血（DIC）进行了全国范围的调查。在新生儿血栓形成中，中心静脉导管并发症是新生儿血栓形成的主要原因之一。应尽早进行新生儿中心静脉导管的管理和预防性抗血栓治疗。组织型纤溶酶原激活剂在新生儿血栓形成中的应用较以往调查有所增加。在新生儿DIC中，新生儿窒息和感染是DIC的两个主要原因，两组间的止血参数有显著差异。但D-二聚体作为诊断标准尚需标准化，血栓调节蛋白治疗对新生儿窒息所致DIC有效，并能改善神经系统预后。并报道了相关研究。TAFI作为血栓形成与纤溶之间的重要因素，其浓度的测定是研究血栓形成与纤溶之间关系的基础。新生儿期TAFI很低。它似乎可以预防新生儿血栓形成。

The national wide survey of neonatal thrombosis and disseminated intravasucular coagulation (DIC) were performed.. In neonatal thrombosis, the complication of central catheter was one of the main causes of neonatal thrombosis. The management and the preventive antithrombotic procedures of neonatal central catheter were needed as soon as possible. The use of tissue plasminogen activator was increased in neonatal thrombosis, comparing with previous survey.. In neonatal DIC, two main causes of DIC were neonatal asphyxisia and infection and the haemostatic parameters were significantly different between these groups. However, the standardization of D-dimer is needed for the diagnostic criteria, Thrombomodulin therapy was effective on DIC induced by neonatal asphyxia and also improved the neurological prognosis. The relative studies were also reported. As the important factor between thrombosis and fibrinolysis, the concentration of TAFI was measured. TAFI was very low in neonatal period. It seems to prevent neonatal thrombosis.